Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Лекарственно-индуцированная артериальная гипертония
Лекарственно-индуцированная артериальная гипертония
Остроумова О.Д., Куликова М.И. Лекарственно-индуцированная артериальная гипертония. Системные гипертензии. 2019; 16 (2): 32–41.
DOI: 10.26442/2075082X.2019.2.180164
Drug-induced arterial hypertension.
Systemic Hypertension. 2019; 16 (2): 32–41.
DOI: 10.26442/2075082X.2019.2.180164
________________________________________________
Drug-induced arterial hypertension.
Systemic Hypertension. 2019; 16 (2): 32–41.
DOI: 10.26442/2075082X.2019.2.180164
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Данный обзор посвящен проблеме лекарственно-индуцированной артериальной гипертонии (АГ). В нем обобщены литературные данные о лекарственных средствах и веществах, которые могут повышать артериальное давление, рассматриваются механизмы их гипертензивного действия. Многие классы лекарственных средств, такие как стероиды, нестероидные противовоспалительные препараты, симпатомиметики, иммунодепрессанты, оральные контрацептивы, антидепрессанты, эритропоэтин и другие, могут вызывать лабильное или стойкое повышение артериального давления, стать причиной неконтролируемой АГ, уменьшать эффективность антигипертензивных препаратов. Развитие лекарственно-индуцированной АГ реализуется посредством ряда патофизиологических механизмов: задержка натрия c последующим увеличением объема циркулирующей крови, активация симпатической нервной системы, прямое воздействие на гладкую мускулатуру артериол, существуют и другие, не до конца изученные механизмы. Лекарственно-индуцированная АГ может также являться результатом фармакокинетического или фармакодинамического взаимодействия лекарственных средств. Подозревать наличие лекарственно-индуцированной АГ, в первую очередь, следует у лиц с впервые диагностированной АГ, а также у пациентов, ранее имевших хорошо контролируемую АГ (стабильные целевые цифры артериального давления – АД) при возникновении у них эпизодов необъяснимого повышения АД без четкой взаимосвязи с физической или психоэмоциональной нагрузкой. Очень важен правильно собранный анамнез с фокусом на тщательную оценку принимаемых пациентом лекарственных средств, особенно вновь назначенных, а также купленных в аптеке самостоятельно, в том числе безрецептурных, это позволит избежать лишних и/или дорогостоящих исследований и ненужных назначений дополнительных антигипертензивных препаратов. В статье приведены меры по профилактике и коррекции лекарственно-индуцированной АГ. Назначение врачом новых лекарственных средств пациентам, получающим антигипертензивную терапию, в обязательном порядке должно учитывать их влияние на риск развития лекарственно-индуцированной АГ. Назначения препаратов, вызывающих повышение АД, следует либо избегать, либо, в том случае, если альтернативные схемы лечения невозможны, обязателен строгий контроль уровня АД у пациента (включая метод домашнего мониторирования АД) и, при необходимости, коррекция проводимой антигипертензивной терапии. При отмене лекарственного средства, вызывающего лекарственно-индуцированную АГ, АД возвращается к исходным значением, что является доказательством ятрогенной причины АГ.
Ключевые слова: артериальная гипертония, лекарственно-индуцированная артериальная гипертония, вторичная артериальная гипертония, лекарственные средства.
Ключевые слова: артериальная гипертония, лекарственно-индуцированная артериальная гипертония, вторичная артериальная гипертония, лекарственные средства.
________________________________________________
Полный текст
Список литературы
1. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339
2. Diaconu CC, Dediu GN, Lancu MA. Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review. Acta Cardiol 2018; 1: 1–7. DOI: 10.1080/00015385.2017.1421445
3. Gyamlani G, Geraci SA. Secondary Hypertension due to Drugs and Toxins. South Med J 2007; 100 (7): 692–9; quiz 700, 708. DOI: 10.1097/SMJ.0b013e318063c3e8
4. Page B, Amoura Z, Grunfeld JP. Effects of corticosteroids on bone and blood pressure. Contrib Nephrol 1992; 99: 60–5.
5. Kaplan NM. Hypertension induced by cortisol or deoxycorticosterone. In Kaplan NM (ed): Clinical Hypertension, 6th edn. Baltimore: Williams & Wilkins, 1994; pp 343–65.
6. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213–24.
7. Whitworth JA, Brown MA, Kelly JJ, Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids 1995; 60 (1): 76–80.
8. Pirpiris M, Sudhir K, Yeung S et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19 (6 Pt 1): 567–74.
9. Клиническая фармакология и фармакотерапия: учеб. для студентов медицинских вузов. Под ред. В.Г.Кукеса, А.К.Стародубцева. М.: ГЭОТАР-Медиа, 2012.
[Klinicheskaia farmakologiia i farmakoterapiia: ucheb. dlia studentov meditsinskikh vuzov. Pod red. V.G.Kukesa, A.K.Starodubtseva. Moscow: GEOTAR-Media, 2012 (in Russian).]
10. Brem AS. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001; 37: 1–10.
11. Ulick S, Levine LS, Gunczler P et al. A syndrome of apparent mineralcorticoid exess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49 (5): 757–64. DOI: 10.1210/jcem-49-5-757
12. Aabo K, De coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralcorticosteroid effect. Lancet 1987; 2: 637–38.
13. Weir RJ. Effect on blood pressure of changing from high to low dose steroid preparations in women with oral contraceptive induced hypertension. Scott Med J 1982; 27: 212–5. DOI: 10.1177/003693308202700303
14. Royal College of General Practitioners Oral Contraceptive Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1: 624.
15. Khaw K, Peart WS. Blood pressure and contraceptive use. Br Med J 1982; 285: 402–7.
16. Spellacy WN, Birk SA. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972; 112: 912–19.
17. Mandel FP, Geola FL, Lu JK et al. Biologic effects of various doses of ethynil estradiol in postmenopausal women. Obster Gynecol 1982; 59: 673-679.
18. Report of the Royal College of General Practitioners. Hypertension. In: Oral contraceptives and health. London: Pitmann, 1974; p. 37–42.
19. Шмелева Е.В., Зиганшина Л.Е., Салихов И.Г. Побочные эффекты гормональных контрацептивов. Казанский мед. журн. 2006; 5: 366–9.
[Shmeleva E.V., Ziganshina L.E., Salikhov I.G. Pobochnye effekty gormonal'nykh kontratseptivov. Kazanskii med. zhurn. 2006; 5: 366–9 (in Russian).]
20. Bretza JA, Novey HS, Vaziri ND, Warner AS. Hypertension: a complication of danazol therapy. Arch Intern Med 1980; 140: 1379–80.
21. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climateric 2003; 6 (Suppl. 3): 49–54.
22. Krattenmaccher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38.
23. Nisenbaum MG, Melo NR, Giribela CR et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 175: 62–6. DOI: 10.1016/j.ejogrb.2014.01.006
24. Preston RA, Alonso A, Panzitta D. Additive effect of drospirenone/17-BETA-estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2002; 15: 816–22.
25. Preston RA, White WB, Pitt B. Effects of drospirenone/17-b estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18 (6): 797–804. DOI: 10.1016/j.amjhyper.2004.12.003
26. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal woman with stage 1 hypertension. Circulation 2005; 112: 1979–1980. DOI: 10.1161/CIRCULATIONAHA.104.501502
27. de Morais TL, Giribela C, Nisenbaum MG et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol 2014; 182: 113–7. DOI: 10.1016/j.ejogrb.2014.09.006
28. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология: учебник для студентов медицинских вузов. М.: МЕДпресс-информ, 2004; с. 391–2.
[Serov V.N., Prilepskaia V.N., Ovsiannikova T.V. Ginekologicheskaia endokrinologiia: uchebnik dlia studentov meditsinskikh vuzov. M.: MEDpress-inform, 2004; s. 391–2 (in Russian).]
29. Кулаков В.И., Кулаков В.И., Сметник В.П. Руководство по климактерию. М.: Медицинское информационное агентство, 2001; с. 404–95.
[Kulakov V.I., Kulakov V.I., Smetnik V.P. Rukovodstvo po klimakteriiu. M.: Meditsinskoe informatsionnoe agentstvo, 2001; s. 404–95 (in Russian).]
30. Барт Б.Я., Бороненков Г.М., Беневская В.Ф. Артериальная гипертония у женщин в постменопаузе: современные возможности медикаментозной терапии в поликлинических условиях. Рос. кардиол. журн. 2001; 5: 69–70.
[Bart B.Ia., Boronenkov G.M., Benevskaia V.F. Arterial'naia gipertoniia u zhenshchin v postmenopauze: sovremennye vozmozhnosti medikamentoznoi terapii v poliklinicheskikh usloviiakh. Ros. kardiol. zhurn. 2001; 5: 69–70 (in Russian).]
31. Курбанова З.К. Влияние низкодозированных комбинированных оральных контрацептивов на эндотелий сосудов. Архив акушерства и гинекологии им. В.Ф.Снегирева. 2015; 4: 46–7.
[Kurbanova Z.K. Vliianie nizkodozirovannykh kombinirovannykh oral'nykh kontratseptivov na endotelii sosudov. Arkhiv akusherstva i ginekologii im. V.F.Snegireva. 2015; 4: 46–7 (in Russian).]
32. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthiritis Long-term programme. Lancet 2006; 18: 771–81. DOI: 10.1016/S0140-6736(06)69666-9
33. Родионов А.В. Нестероидные противовоспалительные препараты и артериальная гипертензия: актуальность проблемы и тактика ведения пациентов. Лечащий врач. 2013; 2.
[Rodionov A.V. Nesteroidnye protivovospalitel'nye preparaty i arterial'naia gipertenziia: aktual'nost' problemy i taktika vedeniia patsientov. Lechashchii vrach. 2013; 2 (in Russian).]
34. White W, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39 (4): 929–34.
35. Sowers J, White W, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165 (2): 161–8. DOI: 10.1001/archinte.165.2.161
36. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011: 236–9. DOI: 10.4061/2011/236239
37. Weber MA. Treatment of patients with hypertension and arthritis pain: new concepts. Am J Med 2009; 122 (Suppl. 5): S16-22. DOI: 10.1016/j.amjmed.2009.03.004
38. Johson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
39. Лазебник Л.Б., Коцюбинская О.Б., Конев О.В., Дроздов В.Н. Влияние нестероидных противовоспалительных препаратов и трамала на уровень артериального давления при лечении остеоартроза у больных с артериальной гипертонией. Научно-практическая ревматология. 2004; 1: 28–33. DOI: 10.14412/1995-4484-2004-1
[Lazebnik L.B., Kotsiubinskaia O.B., Konev O.V., Drozdov V.N. Vliianie nesteroidnykh protivovospalitel'nykh preparatov i tramala na uroven' arterial'nogo davleniia pri lechenii osteoartroza u bol'nykh s arterial'noi gipertoniei. Nauchno-prakticheskaia revmatologiia. 2004; 1: 28–33. DOI: 10.14412/1995-4484-2004-1 (in Russian).]
40. Varas Lorenzo C, Riero-Guardia N, Calingaert B et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225–36. DOI: 10.1002/pds.2227
41. Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8 (6): 173–82. DOI: 10.1177/2042098617690485
42. Еlliot M. Antman AHA Scientific Statements Use of Nosteroidal Antiflammotory Drugs. Circulation 2007; 115 (12): 1634–42. DOI: 10.1161/CIRCULATIONAHA.106.181424
43. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90 (5A): 42S-47S.
44. Wong DG, Spence JD, Lamki L et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; 1: 997–1001.
45. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cuclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–30.
46. Moore N, Salvo F, Duong M et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Exp Opin Drug Saf 2014; 13 (2): 167–79. DOI: 10.1517/14740338.2014.846324
47. Houston MC, Weir M, Gray J et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155 (10): 1049–54.
48. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007; 8: 73. DOI: 10.1186/1471-2474-8-73
49. Furey SA, Vargas R, McMahon FG. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13 (2): 143–8.
50. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии Пифагор IV: приверженность врачей. Рос. кардиол. журн. 2015; 1 (117): 59–66. doi.org/10.15829/1560-4071-2015-1-59-66.
[Leonova M.V., Shteinberg L.L., Belousov Iu.B. i dr. Rezul'taty farmakoepidemiologicheskogo issledovaniia arterial'noi gipertonii Pifagor IV: priverzhennost' vrachei. Ros. kardiol. zhurn. 2015; 1 (117): 59–66. doi.org/10.15829/1560-4071-2015-1-59-66 (in Russian).]
51. Stollberger C, Findterer J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med J 2004; 97 (2): 209–19. doi: 10.1097/01.SMJ.0000093569.26036.27
52. Combe B, Landewe R, Daien CI. 2016 update of the Europian League Against Rheumatism recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76 (6): 948–59. DOI: 10.1136/annrheumdis-2016-210602
53. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64 (4): 465–74.
54. Amsterdam JD, Garcia Espana F, Fawcett J et al. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 1999; 19 (1): 9–14.
55. Kaufmann JS. Letter: Pheochromocytoma and tricyclic antidepressants. JAMA 1974; 229 (10): 1282.
56. Loule AK, Louie EK, Lannon RA. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardilol 1992; 70 (15): 1306–9.
57. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59 (10): 502–8.
58. Roche H, Hyman G, Nahas G. Hypertension and Intravenous antidopaminergic drugs. N Engl J Med 1985; 312 (17): 1125–6.
59. Sheridan C, Chandra P, Jacinto M et al. Transient hypertension after high doses of metoclopramide. N Engl J Med 1982; 307 (21): 1346. DOI: 10.1056/NEJM198211183072118
60. Barjon P, Fourcade J, Mimran A, Charra B. Paroxysmal hypertension during L-dopa treatment in parkinsonism: a metabolic error or a pharmacological effect? Rev Eur Etud Clin Biol 1972; 17 (2): 187–192.
61. Cain JW. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer’s disease. Am J Psychiatry 1986; 143 (7): 910–2. DOI: 10.1176/ajp.143.7.910
62. Scott DL, Smolen JD, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60 (10): 913–23.
63. Akpunonu BE, Mulrow PJ, Hoffman EA. Secondary hypertension: evaluation and treatment: thyrotoxicosis and hypertension. Dis Mon 1996; 42 (10): 689–702.
64. Liu LX, Rustgi AK. Cardiac myonecrosis in hypertensive crisis associated with monoamine oxidase inhibitor therapy. Am J Med 1987; 82 (5): 1060–4.
65. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; 1: CD007893. DOI: 10.1002/14651858
66. Cush JJ, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26 (5): 1176–86.
67. Artz MA, Boots JM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-oflife indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4 (6): 937–45. DOI: 10.1111/j.1600-6143.2004.00427.x
68. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23 (5): 460–8. DOI: 10.1038/ajh.2010.25
69. Wu S, Chen JJ, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9 (2): 117–23. DOI: 10.1016/S1470-2045(08)70003-2
70. Rini BI, Schiller JH, Fruehauf JP et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17 (11): 3841–9. DOI: 10.1158/1078-0432.CCR-10-2806
71. Laragh JH. Renin-Guided Therapy. Clinical Hypertension Review Course Syllabus. Am Soc Hypertens 2005; 353–355.
72. Diaconu C, Nastasa A, Abdul Rehman Z et al. A comparative analysis of the hypertension treatment depending on comorbidities: insights from clinical practice. J Hypertens 2016; 34 (e-Suppl. 1): e320. DOI: 10.1097/01.hjh.0000492280.96930.f6
73. Diaconu C, Istratie B, Nastasa A et al. An age-related comparison between comorbidities and treatment of hypertensive patients. J Hypertens 2016; 34 (e-Suppl. 1): e321. DOI: 10.1097/01.hjh.0000492283.81683.1a.
74. Lowenstein E. Sympathetic nervous system activation and hyperdynamic circulation associated with desflurane: not all isomers are created equal. Anesthesiology 1993; 79 (3): 419–21.
75. Amaranath L, Zanettin GG, Bravo EL et al. Atracurium and pheochromocytoma: a report of three cases. Anesth Analg 1988; 67 (11): 1127–30.
76. Joyce DA, Gubbay SS. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. Br Med J (Clin Res Ed) 1982; 285 (6337): 260–1.
77. Taylor GJ. Cohen Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet Gynecol 1985; 66 (6): 821–2.
78. Bakht FR, Kirshon B, Baker T, Cotton DB. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol 1990; 162 (4): 1065–6.
79. Watson DL, Bhatia RK, Norman GS et al. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol 1989; 74 (4): 573–6.
80. Gorun GS, Dermengiu D, Curca GC et al. Toxicological drivers issues in “legal highs” use. Rom J Leg Med 2010; XVIII (4): 271–9. DOI: 10.4323/rjlm.2010.271
81. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98 (1): 1–14. DOI: 10.1016/j.ijcard.2003.06.039
82. Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2012; 120 (4): 494–500. DOI: 10.1289/ehp.1103988
83. Sofer S, Shalev H, Weizman Z et al. Acute pancreatitis in children following envenomation by the yellow scorpion Leiurus quinquestriatus. Toxicon 1991; 29 (1): 125–8.
84. Saadeh AM, Farsakh NA, al-Ali MK. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart 1997; 77 (5) :461–4.
85. World Hypertension League: Nonpharmacological interventions as an adjunct to the pharmacological treatment of hypertension. J Hum Hypertens 1993; 7 (2): 159–64.
86. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125 (1): 14–22. DOI: 10.1016/j.amjmed.2011.05.02
87. Lancu MA, Diaconu C, Dediu G et al. An analysis of hypertensive male patients addresses to a primary practice. J Hypertens 2016; 34 (e-Supplement 2): e323. DOI: 10.1097/01.hjh.0000492291.09500.3a
2. Diaconu CC, Dediu GN, Lancu MA. Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review. Acta Cardiol 2018; 1: 1–7. DOI: 10.1080/00015385.2017.1421445
3. Gyamlani G, Geraci SA. Secondary Hypertension due to Drugs and Toxins. South Med J 2007; 100 (7): 692–9; quiz 700, 708. DOI: 10.1097/SMJ.0b013e318063c3e8
4. Page B, Amoura Z, Grunfeld JP. Effects of corticosteroids on bone and blood pressure. Contrib Nephrol 1992; 99: 60–5.
5. Kaplan NM. Hypertension induced by cortisol or deoxycorticosterone. In Kaplan NM (ed): Clinical Hypertension, 6th edn. Baltimore: Williams & Wilkins, 1994; pp 343–65.
6. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213–24.
7. Whitworth JA, Brown MA, Kelly JJ, Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids 1995; 60 (1): 76–80.
8. Pirpiris M, Sudhir K, Yeung S et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19 (6 Pt 1): 567–74.
9.Klinicheskaia farmakologiia i farmakoterapiia: ucheb. dlia studentov meditsinskikh vuzov. Pod red. V.G.Kukesa, A.K.Starodubtseva. Moscow: GEOTAR-Media, 2012 (in Russian).
10. Brem AS. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001; 37: 1–10.
11. Ulick S, Levine LS, Gunczler P et al. A syndrome of apparent mineralcorticoid exess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49 (5): 757–64. DOI: 10.1210/jcem-49-5-757
12. Aabo K, De coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralcorticosteroid effect. Lancet 1987; 2: 637–38.
13. Weir RJ. Effect on blood pressure of changing from high to low dose steroid preparations in women with oral contraceptive induced hypertension. Scott Med J 1982; 27: 212–5. DOI: 10.1177/003693308202700303
14. Royal College of General Practitioners Oral Contraceptive Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1: 624.
15. Khaw K, Peart WS. Blood pressure and contraceptive use. Br Med J 1982; 285: 402–7.
16. Spellacy WN, Birk SA. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972; 112: 912–19.
17. Mandel FP, Geola FL, Lu JK et al. Biologic effects of various doses of ethynil estradiol in postmenopausal women. Obster Gynecol 1982; 59: 673-679.
18. Report of the Royal College of General Practitioners. Hypertension. In: Oral contraceptives and health. London: Pitmann, 1974; p. 37–42.
19. Shmeleva E.V., Ziganshina L.E., Salikhov I.G. Pobochnye effekty gormonal'nykh kontratseptivov. Kazanskii med. zhurn. 2006; 5: 366–9 (in Russian).
20. Bretza JA, Novey HS, Vaziri ND, Warner AS. Hypertension: a complication of danazol therapy. Arch Intern Med 1980; 140: 1379–80.
21. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climateric 2003; 6 (Suppl. 3): 49–54.
22. Krattenmaccher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38.
23. Nisenbaum MG, Melo NR, Giribela CR et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 175: 62–6. DOI: 10.1016/j.ejogrb.2014.01.006
24. Preston RA, Alonso A, Panzitta D. Additive effect of drospirenone/17-BETA-estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2002; 15: 816–22.
25. Preston RA, White WB, Pitt B. Effects of drospirenone/17-b estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18 (6): 797–804. DOI: 10.1016/j.amjhyper.2004.12.003
26. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal woman with stage 1 hypertension. Circulation 2005; 112: 1979–1980. DOI: 10.1161/CIRCULATIONAHA.104.501502
27. de Morais TL, Giribela C, Nisenbaum MG et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol 2014; 182: 113–7. DOI: 10.1016/j.ejogrb.2014.09.006
28. Serov V.N., Prilepskaia V.N., Ovsiannikova T.V. Ginekologicheskaia endokrinologiia: uchebnik dlia studentov meditsinskikh vuzov. M.: MEDpress-inform, 2004; s. 391–2 (in Russian).
29. Kulakov V.I., Kulakov V.I., Smetnik V.P. Rukovodstvo po klimakteriiu. M.: Meditsinskoe informatsionnoe agentstvo, 2001; s. 404–95 (in Russian).
30. Bart B.Ia., Boronenkov G.M., Benevskaia V.F. Arterial'naia gipertoniia u zhenshchin v postmenopauze: sovremennye vozmozhnosti medikamentoznoi terapii v poliklinicheskikh usloviiakh. Ros. kardiol. zhurn. 2001; 5: 69–70 (in Russian).
31. Kurbanova Z.K. Vliianie nizkodozirovannykh kombinirovannykh oral'nykh kontratseptivov na endotelii sosudov. Arkhiv akusherstva i ginekologii im. V.F.Snegireva. 2015; 4: 46–7 (in Russian).
32. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthiritis Long-term programme. Lancet 2006; 18: 771–81. DOI: 10.1016/S0140-6736(06)69666-9
33. Rodionov A.V. Nesteroidnye protivovospalitel'nye preparaty i arterial'naia gipertenziia: aktual'nost' problemy i taktika vedeniia patsientov. Lechashchii vrach. 2013; 2 (in Russian).
34. White W, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39 (4): 929–34.
35. Sowers J, White W, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165 (2): 161–8. DOI: 10.1001/archinte.165.2.161
36. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011: 236–9. DOI: 10.4061/2011/236239
37. Weber MA. Treatment of patients with hypertension and arthritis pain: new concepts. Am J Med 2009; 122 (Suppl. 5): S16-22. DOI: 10.1016/j.amjmed.2009.03.004
38. Johson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
39. Lazebnik L.B., Kotsiubinskaia O.B., Konev O.V., Drozdov V.N. Vliianie nesteroidnykh protivovospalitel'nykh preparatov i tramala na uroven' arterial'nogo davleniia pri lechenii osteoartroza u bol'nykh s arterial'noi gipertoniei. Nauchno-prakticheskaia revmatologiia. 2004; 1: 28–33. DOI: 10.14412/1995-4484-2004-1 (in Russian).
40. Varas Lorenzo C, Riero-Guardia N, Calingaert B et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225–36. DOI: 10.1002/pds.2227
41. Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8 (6): 173–82. DOI: 10.1177/2042098617690485
42. Еlliot M. Antman AHA Scientific Statements Use of Nosteroidal Antiflammotory Drugs. Circulation 2007; 115 (12): 1634–42. DOI: 10.1161/CIRCULATIONAHA.106.181424
43. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90 (5A): 42S-47S.
44. Wong DG, Spence JD, Lamki L et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; 1: 997–1001.
45. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cuclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–30.
46. Moore N, Salvo F, Duong M et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Exp Opin Drug Saf 2014; 13 (2): 167–79. DOI: 10.1517/14740338.2014.846324
47. Houston MC, Weir M, Gray J et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155 (10): 1049–54.
48. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007; 8: 73. DOI: 10.1186/1471-2474-8-73
49. Furey SA, Vargas R, McMahon FG. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13 (2): 143–8.
50. Leonova M.V., Shteinberg L.L., Belousov Iu.B. i dr. Rezul'taty farmakoepidemiologicheskogo issledovaniia arterial'noi gipertonii Pifagor IV: priverzhennost' vrachei. Ros. kardiol. zhurn. 2015; 1 (117): 59–66. doi.org/10.15829/1560-4071-2015-1-59-66 (in Russian).
51. Stollberger C, Findterer J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med J 2004; 97 (2): 209–19. doi: 10.1097/01.SMJ.0000093569.26036.27
52. Combe B, Landewe R, Daien CI. 2016 update of the Europian League Against Rheumatism recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76 (6): 948–59. DOI: 10.1136/annrheumdis-2016-210602
53. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64 (4): 465–74.
54. Amsterdam JD, Garcia Espana F, Fawcett J et al. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 1999; 19 (1): 9–14.
55. Kaufmann JS. Letter: Pheochromocytoma and tricyclic antidepressants. JAMA 1974; 229 (10): 1282.
56. Loule AK, Louie EK, Lannon RA. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardilol 1992; 70 (15): 1306–9.
57. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59 (10): 502–8.
58. Roche H, Hyman G, Nahas G. Hypertension and Intravenous antidopaminergic drugs. N Engl J Med 1985; 312 (17): 1125–6.
59. Sheridan C, Chandra P, Jacinto M et al. Transient hypertension after high doses of metoclopramide. N Engl J Med 1982; 307 (21): 1346. DOI: 10.1056/NEJM198211183072118
60. Barjon P, Fourcade J, Mimran A, Charra B. Paroxysmal hypertension during L-dopa treatment in parkinsonism: a metabolic error or a pharmacological effect? Rev Eur Etud Clin Biol 1972; 17 (2): 187–192.
61. Cain JW. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer’s disease. Am J Psychiatry 1986; 143 (7): 910–2. DOI: 10.1176/ajp.143.7.910
62. Scott DL, Smolen JD, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60 (10): 913–23.
63. Akpunonu BE, Mulrow PJ, Hoffman EA. Secondary hypertension: evaluation and treatment: thyrotoxicosis and hypertension. Dis Mon 1996; 42 (10): 689–702.
64. Liu LX, Rustgi AK. Cardiac myonecrosis in hypertensive crisis associated with monoamine oxidase inhibitor therapy. Am J Med 1987; 82 (5): 1060–4.
65. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; 1: CD007893. DOI: 10.1002/14651858
66. Cush JJ, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26 (5): 1176–86.
67. Artz MA, Boots JM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-oflife indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4 (6): 937–45. DOI: 10.1111/j.1600-6143.2004.00427.x
68. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23 (5): 460–8. DOI: 10.1038/ajh.2010.25
69. Wu S, Chen JJ, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9 (2): 117–23. DOI: 10.1016/S1470-2045(08)70003-2
70. Rini BI, Schiller JH, Fruehauf JP et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17 (11): 3841–9. DOI: 10.1158/1078-0432.CCR-10-2806
71. Laragh JH. Renin-Guided Therapy. Clinical Hypertension Review Course Syllabus. Am Soc Hypertens 2005; 353–355.
72. Diaconu C, Nastasa A, Abdul Rehman Z et al. A comparative analysis of the hypertension treatment depending on comorbidities: insights from clinical practice. J Hypertens 2016; 34 (e-Suppl. 1): e320. DOI: 10.1097/01.hjh.0000492280.96930.f6
73. Diaconu C, Istratie B, Nastasa A et al. An age-related comparison between comorbidities and treatment of hypertensive patients. J Hypertens 2016; 34 (e-Suppl. 1): e321. DOI: 10.1097/01.hjh.0000492283.81683.1a.
74. Lowenstein E. Sympathetic nervous system activation and hyperdynamic circulation associated with desflurane: not all isomers are created equal. Anesthesiology 1993; 79 (3): 419–21.
75. Amaranath L, Zanettin GG, Bravo EL et al. Atracurium and pheochromocytoma: a report of three cases. Anesth Analg 1988; 67 (11): 1127–30.
76. Joyce DA, Gubbay SS. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. Br Med J (Clin Res Ed) 1982; 285 (6337): 260–1.
77. Taylor GJ. Cohen Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet Gynecol 1985; 66 (6): 821–2.
78. Bakht FR, Kirshon B, Baker T, Cotton DB. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol 1990; 162 (4): 1065–6.
79. Watson DL, Bhatia RK, Norman GS et al. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol 1989; 74 (4): 573–6.
80. Gorun GS, Dermengiu D, Curca GC et al. Toxicological drivers issues in “legal highs” use. Rom J Leg Med 2010; XVIII (4): 271–9. DOI: 10.4323/rjlm.2010.271
81. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98 (1): 1–14. DOI: 10.1016/j.ijcard.2003.06.039
82. Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2012; 120 (4): 494–500. DOI: 10.1289/ehp.1103988
83. Sofer S, Shalev H, Weizman Z et al. Acute pancreatitis in children following envenomation by the yellow scorpion Leiurus quinquestriatus. Toxicon 1991; 29 (1): 125–8.
84. Saadeh AM, Farsakh NA, al-Ali MK. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart 1997; 77 (5) :461–4.
85. World Hypertension League: Nonpharmacological interventions as an adjunct to the pharmacological treatment of hypertension. J Hum Hypertens 1993; 7 (2): 159–64.
86. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125 (1): 14–22. DOI: 10.1016/j.amjmed.2011.05.02
87. Lancu MA, Diaconu C, Dediu G et al. An analysis of hypertensive male patients addresses to a primary practice. J Hypertens 2016; 34 (e-Supplement 2): e323. DOI: 10.1097/01.hjh.0000492291.09500.3a
2. Diaconu CC, Dediu GN, Lancu MA. Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review. Acta Cardiol 2018; 1: 1–7. DOI: 10.1080/00015385.2017.1421445
3. Gyamlani G, Geraci SA. Secondary Hypertension due to Drugs and Toxins. South Med J 2007; 100 (7): 692–9; quiz 700, 708. DOI: 10.1097/SMJ.0b013e318063c3e8
4. Page B, Amoura Z, Grunfeld JP. Effects of corticosteroids on bone and blood pressure. Contrib Nephrol 1992; 99: 60–5.
5. Kaplan NM. Hypertension induced by cortisol or deoxycorticosterone. In Kaplan NM (ed): Clinical Hypertension, 6th edn. Baltimore: Williams & Wilkins, 1994; pp 343–65.
6. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213–24.
7. Whitworth JA, Brown MA, Kelly JJ, Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids 1995; 60 (1): 76–80.
8. Pirpiris M, Sudhir K, Yeung S et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19 (6 Pt 1): 567–74.
9. Клиническая фармакология и фармакотерапия: учеб. для студентов медицинских вузов. Под ред. В.Г.Кукеса, А.К.Стародубцева. М.: ГЭОТАР-Медиа, 2012.
[Klinicheskaia farmakologiia i farmakoterapiia: ucheb. dlia studentov meditsinskikh vuzov. Pod red. V.G.Kukesa, A.K.Starodubtseva. Moscow: GEOTAR-Media, 2012 (in Russian).]
10. Brem AS. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001; 37: 1–10.
11. Ulick S, Levine LS, Gunczler P et al. A syndrome of apparent mineralcorticoid exess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49 (5): 757–64. DOI: 10.1210/jcem-49-5-757
12. Aabo K, De coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralcorticosteroid effect. Lancet 1987; 2: 637–38.
13. Weir RJ. Effect on blood pressure of changing from high to low dose steroid preparations in women with oral contraceptive induced hypertension. Scott Med J 1982; 27: 212–5. DOI: 10.1177/003693308202700303
14. Royal College of General Practitioners Oral Contraceptive Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1: 624.
15. Khaw K, Peart WS. Blood pressure and contraceptive use. Br Med J 1982; 285: 402–7.
16. Spellacy WN, Birk SA. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972; 112: 912–19.
17. Mandel FP, Geola FL, Lu JK et al. Biologic effects of various doses of ethynil estradiol in postmenopausal women. Obster Gynecol 1982; 59: 673-679.
18. Report of the Royal College of General Practitioners. Hypertension. In: Oral contraceptives and health. London: Pitmann, 1974; p. 37–42.
19. Шмелева Е.В., Зиганшина Л.Е., Салихов И.Г. Побочные эффекты гормональных контрацептивов. Казанский мед. журн. 2006; 5: 366–9.
[Shmeleva E.V., Ziganshina L.E., Salikhov I.G. Pobochnye effekty gormonal'nykh kontratseptivov. Kazanskii med. zhurn. 2006; 5: 366–9 (in Russian).]
20. Bretza JA, Novey HS, Vaziri ND, Warner AS. Hypertension: a complication of danazol therapy. Arch Intern Med 1980; 140: 1379–80.
21. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climateric 2003; 6 (Suppl. 3): 49–54.
22. Krattenmaccher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38.
23. Nisenbaum MG, Melo NR, Giribela CR et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 175: 62–6. DOI: 10.1016/j.ejogrb.2014.01.006
24. Preston RA, Alonso A, Panzitta D. Additive effect of drospirenone/17-BETA-estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2002; 15: 816–22.
25. Preston RA, White WB, Pitt B. Effects of drospirenone/17-b estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18 (6): 797–804. DOI: 10.1016/j.amjhyper.2004.12.003
26. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal woman with stage 1 hypertension. Circulation 2005; 112: 1979–1980. DOI: 10.1161/CIRCULATIONAHA.104.501502
27. de Morais TL, Giribela C, Nisenbaum MG et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol 2014; 182: 113–7. DOI: 10.1016/j.ejogrb.2014.09.006
28. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология: учебник для студентов медицинских вузов. М.: МЕДпресс-информ, 2004; с. 391–2.
[Serov V.N., Prilepskaia V.N., Ovsiannikova T.V. Ginekologicheskaia endokrinologiia: uchebnik dlia studentov meditsinskikh vuzov. M.: MEDpress-inform, 2004; s. 391–2 (in Russian).]
29. Кулаков В.И., Кулаков В.И., Сметник В.П. Руководство по климактерию. М.: Медицинское информационное агентство, 2001; с. 404–95.
[Kulakov V.I., Kulakov V.I., Smetnik V.P. Rukovodstvo po klimakteriiu. M.: Meditsinskoe informatsionnoe agentstvo, 2001; s. 404–95 (in Russian).]
30. Барт Б.Я., Бороненков Г.М., Беневская В.Ф. Артериальная гипертония у женщин в постменопаузе: современные возможности медикаментозной терапии в поликлинических условиях. Рос. кардиол. журн. 2001; 5: 69–70.
[Bart B.Ia., Boronenkov G.M., Benevskaia V.F. Arterial'naia gipertoniia u zhenshchin v postmenopauze: sovremennye vozmozhnosti medikamentoznoi terapii v poliklinicheskikh usloviiakh. Ros. kardiol. zhurn. 2001; 5: 69–70 (in Russian).]
31. Курбанова З.К. Влияние низкодозированных комбинированных оральных контрацептивов на эндотелий сосудов. Архив акушерства и гинекологии им. В.Ф.Снегирева. 2015; 4: 46–7.
[Kurbanova Z.K. Vliianie nizkodozirovannykh kombinirovannykh oral'nykh kontratseptivov na endotelii sosudov. Arkhiv akusherstva i ginekologii im. V.F.Snegireva. 2015; 4: 46–7 (in Russian).]
32. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthiritis Long-term programme. Lancet 2006; 18: 771–81. DOI: 10.1016/S0140-6736(06)69666-9
33. Родионов А.В. Нестероидные противовоспалительные препараты и артериальная гипертензия: актуальность проблемы и тактика ведения пациентов. Лечащий врач. 2013; 2.
[Rodionov A.V. Nesteroidnye protivovospalitel'nye preparaty i arterial'naia gipertenziia: aktual'nost' problemy i taktika vedeniia patsientov. Lechashchii vrach. 2013; 2 (in Russian).]
34. White W, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39 (4): 929–34.
35. Sowers J, White W, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165 (2): 161–8. DOI: 10.1001/archinte.165.2.161
36. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011: 236–9. DOI: 10.4061/2011/236239
37. Weber MA. Treatment of patients with hypertension and arthritis pain: new concepts. Am J Med 2009; 122 (Suppl. 5): S16-22. DOI: 10.1016/j.amjmed.2009.03.004
38. Johson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
39. Лазебник Л.Б., Коцюбинская О.Б., Конев О.В., Дроздов В.Н. Влияние нестероидных противовоспалительных препаратов и трамала на уровень артериального давления при лечении остеоартроза у больных с артериальной гипертонией. Научно-практическая ревматология. 2004; 1: 28–33. DOI: 10.14412/1995-4484-2004-1
[Lazebnik L.B., Kotsiubinskaia O.B., Konev O.V., Drozdov V.N. Vliianie nesteroidnykh protivovospalitel'nykh preparatov i tramala na uroven' arterial'nogo davleniia pri lechenii osteoartroza u bol'nykh s arterial'noi gipertoniei. Nauchno-prakticheskaia revmatologiia. 2004; 1: 28–33. DOI: 10.14412/1995-4484-2004-1 (in Russian).]
40. Varas Lorenzo C, Riero-Guardia N, Calingaert B et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225–36. DOI: 10.1002/pds.2227
41. Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8 (6): 173–82. DOI: 10.1177/2042098617690485
42. Еlliot M. Antman AHA Scientific Statements Use of Nosteroidal Antiflammotory Drugs. Circulation 2007; 115 (12): 1634–42. DOI: 10.1161/CIRCULATIONAHA.106.181424
43. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90 (5A): 42S-47S.
44. Wong DG, Spence JD, Lamki L et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; 1: 997–1001.
45. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cuclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–30.
46. Moore N, Salvo F, Duong M et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Exp Opin Drug Saf 2014; 13 (2): 167–79. DOI: 10.1517/14740338.2014.846324
47. Houston MC, Weir M, Gray J et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155 (10): 1049–54.
48. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007; 8: 73. DOI: 10.1186/1471-2474-8-73
49. Furey SA, Vargas R, McMahon FG. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13 (2): 143–8.
50. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии Пифагор IV: приверженность врачей. Рос. кардиол. журн. 2015; 1 (117): 59–66. doi.org/10.15829/1560-4071-2015-1-59-66.
[Leonova M.V., Shteinberg L.L., Belousov Iu.B. i dr. Rezul'taty farmakoepidemiologicheskogo issledovaniia arterial'noi gipertonii Pifagor IV: priverzhennost' vrachei. Ros. kardiol. zhurn. 2015; 1 (117): 59–66. doi.org/10.15829/1560-4071-2015-1-59-66 (in Russian).]
51. Stollberger C, Findterer J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med J 2004; 97 (2): 209–19. doi: 10.1097/01.SMJ.0000093569.26036.27
52. Combe B, Landewe R, Daien CI. 2016 update of the Europian League Against Rheumatism recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76 (6): 948–59. DOI: 10.1136/annrheumdis-2016-210602
53. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64 (4): 465–74.
54. Amsterdam JD, Garcia Espana F, Fawcett J et al. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 1999; 19 (1): 9–14.
55. Kaufmann JS. Letter: Pheochromocytoma and tricyclic antidepressants. JAMA 1974; 229 (10): 1282.
56. Loule AK, Louie EK, Lannon RA. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardilol 1992; 70 (15): 1306–9.
57. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59 (10): 502–8.
58. Roche H, Hyman G, Nahas G. Hypertension and Intravenous antidopaminergic drugs. N Engl J Med 1985; 312 (17): 1125–6.
59. Sheridan C, Chandra P, Jacinto M et al. Transient hypertension after high doses of metoclopramide. N Engl J Med 1982; 307 (21): 1346. DOI: 10.1056/NEJM198211183072118
60. Barjon P, Fourcade J, Mimran A, Charra B. Paroxysmal hypertension during L-dopa treatment in parkinsonism: a metabolic error or a pharmacological effect? Rev Eur Etud Clin Biol 1972; 17 (2): 187–192.
61. Cain JW. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer’s disease. Am J Psychiatry 1986; 143 (7): 910–2. DOI: 10.1176/ajp.143.7.910
62. Scott DL, Smolen JD, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60 (10): 913–23.
63. Akpunonu BE, Mulrow PJ, Hoffman EA. Secondary hypertension: evaluation and treatment: thyrotoxicosis and hypertension. Dis Mon 1996; 42 (10): 689–702.
64. Liu LX, Rustgi AK. Cardiac myonecrosis in hypertensive crisis associated with monoamine oxidase inhibitor therapy. Am J Med 1987; 82 (5): 1060–4.
65. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; 1: CD007893. DOI: 10.1002/14651858
66. Cush JJ, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26 (5): 1176–86.
67. Artz MA, Boots JM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-oflife indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4 (6): 937–45. DOI: 10.1111/j.1600-6143.2004.00427.x
68. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23 (5): 460–8. DOI: 10.1038/ajh.2010.25
69. Wu S, Chen JJ, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9 (2): 117–23. DOI: 10.1016/S1470-2045(08)70003-2
70. Rini BI, Schiller JH, Fruehauf JP et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17 (11): 3841–9. DOI: 10.1158/1078-0432.CCR-10-2806
71. Laragh JH. Renin-Guided Therapy. Clinical Hypertension Review Course Syllabus. Am Soc Hypertens 2005; 353–355.
72. Diaconu C, Nastasa A, Abdul Rehman Z et al. A comparative analysis of the hypertension treatment depending on comorbidities: insights from clinical practice. J Hypertens 2016; 34 (e-Suppl. 1): e320. DOI: 10.1097/01.hjh.0000492280.96930.f6
73. Diaconu C, Istratie B, Nastasa A et al. An age-related comparison between comorbidities and treatment of hypertensive patients. J Hypertens 2016; 34 (e-Suppl. 1): e321. DOI: 10.1097/01.hjh.0000492283.81683.1a.
74. Lowenstein E. Sympathetic nervous system activation and hyperdynamic circulation associated with desflurane: not all isomers are created equal. Anesthesiology 1993; 79 (3): 419–21.
75. Amaranath L, Zanettin GG, Bravo EL et al. Atracurium and pheochromocytoma: a report of three cases. Anesth Analg 1988; 67 (11): 1127–30.
76. Joyce DA, Gubbay SS. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. Br Med J (Clin Res Ed) 1982; 285 (6337): 260–1.
77. Taylor GJ. Cohen Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet Gynecol 1985; 66 (6): 821–2.
78. Bakht FR, Kirshon B, Baker T, Cotton DB. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol 1990; 162 (4): 1065–6.
79. Watson DL, Bhatia RK, Norman GS et al. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol 1989; 74 (4): 573–6.
80. Gorun GS, Dermengiu D, Curca GC et al. Toxicological drivers issues in “legal highs” use. Rom J Leg Med 2010; XVIII (4): 271–9. DOI: 10.4323/rjlm.2010.271
81. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98 (1): 1–14. DOI: 10.1016/j.ijcard.2003.06.039
82. Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2012; 120 (4): 494–500. DOI: 10.1289/ehp.1103988
83. Sofer S, Shalev H, Weizman Z et al. Acute pancreatitis in children following envenomation by the yellow scorpion Leiurus quinquestriatus. Toxicon 1991; 29 (1): 125–8.
84. Saadeh AM, Farsakh NA, al-Ali MK. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart 1997; 77 (5) :461–4.
85. World Hypertension League: Nonpharmacological interventions as an adjunct to the pharmacological treatment of hypertension. J Hum Hypertens 1993; 7 (2): 159–64.
86. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125 (1): 14–22. DOI: 10.1016/j.amjmed.2011.05.02
87. Lancu MA, Diaconu C, Dediu G et al. An analysis of hypertensive male patients addresses to a primary practice. J Hypertens 2016; 34 (e-Supplement 2): e323. DOI: 10.1097/01.hjh.0000492291.09500.3a
________________________________________________
2. Diaconu CC, Dediu GN, Lancu MA. Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review. Acta Cardiol 2018; 1: 1–7. DOI: 10.1080/00015385.2017.1421445
3. Gyamlani G, Geraci SA. Secondary Hypertension due to Drugs and Toxins. South Med J 2007; 100 (7): 692–9; quiz 700, 708. DOI: 10.1097/SMJ.0b013e318063c3e8
4. Page B, Amoura Z, Grunfeld JP. Effects of corticosteroids on bone and blood pressure. Contrib Nephrol 1992; 99: 60–5.
5. Kaplan NM. Hypertension induced by cortisol or deoxycorticosterone. In Kaplan NM (ed): Clinical Hypertension, 6th edn. Baltimore: Williams & Wilkins, 1994; pp 343–65.
6. Whitworth JA. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213–24.
7. Whitworth JA, Brown MA, Kelly JJ, Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids 1995; 60 (1): 76–80.
8. Pirpiris M, Sudhir K, Yeung S et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19 (6 Pt 1): 567–74.
9.Klinicheskaia farmakologiia i farmakoterapiia: ucheb. dlia studentov meditsinskikh vuzov. Pod red. V.G.Kukesa, A.K.Starodubtseva. Moscow: GEOTAR-Media, 2012 (in Russian).
10. Brem AS. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001; 37: 1–10.
11. Ulick S, Levine LS, Gunczler P et al. A syndrome of apparent mineralcorticoid exess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49 (5): 757–64. DOI: 10.1210/jcem-49-5-757
12. Aabo K, De coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralcorticosteroid effect. Lancet 1987; 2: 637–38.
13. Weir RJ. Effect on blood pressure of changing from high to low dose steroid preparations in women with oral contraceptive induced hypertension. Scott Med J 1982; 27: 212–5. DOI: 10.1177/003693308202700303
14. Royal College of General Practitioners Oral Contraceptive Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1: 624.
15. Khaw K, Peart WS. Blood pressure and contraceptive use. Br Med J 1982; 285: 402–7.
16. Spellacy WN, Birk SA. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972; 112: 912–19.
17. Mandel FP, Geola FL, Lu JK et al. Biologic effects of various doses of ethynil estradiol in postmenopausal women. Obster Gynecol 1982; 59: 673-679.
18. Report of the Royal College of General Practitioners. Hypertension. In: Oral contraceptives and health. London: Pitmann, 1974; p. 37–42.
19. Shmeleva E.V., Ziganshina L.E., Salikhov I.G. Pobochnye effekty gormonal'nykh kontratseptivov. Kazanskii med. zhurn. 2006; 5: 366–9 (in Russian).
20. Bretza JA, Novey HS, Vaziri ND, Warner AS. Hypertension: a complication of danazol therapy. Arch Intern Med 1980; 140: 1379–80.
21. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climateric 2003; 6 (Suppl. 3): 49–54.
22. Krattenmaccher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29–38.
23. Nisenbaum MG, Melo NR, Giribela CR et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 175: 62–6. DOI: 10.1016/j.ejogrb.2014.01.006
24. Preston RA, Alonso A, Panzitta D. Additive effect of drospirenone/17-BETA-estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2002; 15: 816–22.
25. Preston RA, White WB, Pitt B. Effects of drospirenone/17-b estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18 (6): 797–804. DOI: 10.1016/j.amjhyper.2004.12.003
26. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal woman with stage 1 hypertension. Circulation 2005; 112: 1979–1980. DOI: 10.1161/CIRCULATIONAHA.104.501502
27. de Morais TL, Giribela C, Nisenbaum MG et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol 2014; 182: 113–7. DOI: 10.1016/j.ejogrb.2014.09.006
28. Serov V.N., Prilepskaia V.N., Ovsiannikova T.V. Ginekologicheskaia endokrinologiia: uchebnik dlia studentov meditsinskikh vuzov. M.: MEDpress-inform, 2004; s. 391–2 (in Russian).
29. Kulakov V.I., Kulakov V.I., Smetnik V.P. Rukovodstvo po klimakteriiu. M.: Meditsinskoe informatsionnoe agentstvo, 2001; s. 404–95 (in Russian).
30. Bart B.Ia., Boronenkov G.M., Benevskaia V.F. Arterial'naia gipertoniia u zhenshchin v postmenopauze: sovremennye vozmozhnosti medikamentoznoi terapii v poliklinicheskikh usloviiakh. Ros. kardiol. zhurn. 2001; 5: 69–70 (in Russian).
31. Kurbanova Z.K. Vliianie nizkodozirovannykh kombinirovannykh oral'nykh kontratseptivov na endotelii sosudov. Arkhiv akusherstva i ginekologii im. V.F.Snegireva. 2015; 4: 46–7 (in Russian).
32. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthiritis Long-term programme. Lancet 2006; 18: 771–81. DOI: 10.1016/S0140-6736(06)69666-9
33. Rodionov A.V. Nesteroidnye protivovospalitel'nye preparaty i arterial'naia gipertenziia: aktual'nost' problemy i taktika vedeniia patsientov. Lechashchii vrach. 2013; 2 (in Russian).
34. White W, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39 (4): 929–34.
35. Sowers J, White W, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165 (2): 161–8. DOI: 10.1001/archinte.165.2.161
36. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011: 236–9. DOI: 10.4061/2011/236239
37. Weber MA. Treatment of patients with hypertension and arthritis pain: new concepts. Am J Med 2009; 122 (Suppl. 5): S16-22. DOI: 10.1016/j.amjmed.2009.03.004
38. Johson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.
39. Lazebnik L.B., Kotsiubinskaia O.B., Konev O.V., Drozdov V.N. Vliianie nesteroidnykh protivovospalitel'nykh preparatov i tramala na uroven' arterial'nogo davleniia pri lechenii osteoartroza u bol'nykh s arterial'noi gipertoniei. Nauchno-prakticheskaia revmatologiia. 2004; 1: 28–33. DOI: 10.14412/1995-4484-2004-1 (in Russian).
40. Varas Lorenzo C, Riero-Guardia N, Calingaert B et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225–36. DOI: 10.1002/pds.2227
41. Fanelli A, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8 (6): 173–82. DOI: 10.1177/2042098617690485
42. Еlliot M. Antman AHA Scientific Statements Use of Nosteroidal Antiflammotory Drugs. Circulation 2007; 115 (12): 1634–42. DOI: 10.1161/CIRCULATIONAHA.106.181424
43. Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90 (5A): 42S-47S.
44. Wong DG, Spence JD, Lamki L et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; 1: 997–1001.
45. White WB, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cuclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425–30.
46. Moore N, Salvo F, Duong M et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Exp Opin Drug Saf 2014; 13 (2): 167–79. DOI: 10.1517/14740338.2014.846324
47. Houston MC, Weir M, Gray J et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155 (10): 1049–54.
48. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007; 8: 73. DOI: 10.1186/1471-2474-8-73
49. Furey SA, Vargas R, McMahon FG. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13 (2): 143–8.
50. Leonova M.V., Shteinberg L.L., Belousov Iu.B. i dr. Rezul'taty farmakoepidemiologicheskogo issledovaniia arterial'noi gipertonii Pifagor IV: priverzhennost' vrachei. Ros. kardiol. zhurn. 2015; 1 (117): 59–66. doi.org/10.15829/1560-4071-2015-1-59-66 (in Russian).
51. Stollberger C, Findterer J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med J 2004; 97 (2): 209–19. doi: 10.1097/01.SMJ.0000093569.26036.27
52. Combe B, Landewe R, Daien CI. 2016 update of the Europian League Against Rheumatism recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76 (6): 948–59. DOI: 10.1136/annrheumdis-2016-210602
53. Hochberg MC, Altman RD, April KT et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64 (4): 465–74.
54. Amsterdam JD, Garcia Espana F, Fawcett J et al. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 1999; 19 (1): 9–14.
55. Kaufmann JS. Letter: Pheochromocytoma and tricyclic antidepressants. JAMA 1974; 229 (10): 1282.
56. Loule AK, Louie EK, Lannon RA. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardilol 1992; 70 (15): 1306–9.
57. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59 (10): 502–8.
58. Roche H, Hyman G, Nahas G. Hypertension and Intravenous antidopaminergic drugs. N Engl J Med 1985; 312 (17): 1125–6.
59. Sheridan C, Chandra P, Jacinto M et al. Transient hypertension after high doses of metoclopramide. N Engl J Med 1982; 307 (21): 1346. DOI: 10.1056/NEJM198211183072118
60. Barjon P, Fourcade J, Mimran A, Charra B. Paroxysmal hypertension during L-dopa treatment in parkinsonism: a metabolic error or a pharmacological effect? Rev Eur Etud Clin Biol 1972; 17 (2): 187–192.
61. Cain JW. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer’s disease. Am J Psychiatry 1986; 143 (7): 910–2. DOI: 10.1176/ajp.143.7.910
62. Scott DL, Smolen JD, Kalden JR et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60 (10): 913–23.
63. Akpunonu BE, Mulrow PJ, Hoffman EA. Secondary hypertension: evaluation and treatment: thyrotoxicosis and hypertension. Dis Mon 1996; 42 (10): 689–702.
64. Liu LX, Rustgi AK. Cardiac myonecrosis in hypertensive crisis associated with monoamine oxidase inhibitor therapy. Am J Med 1987; 82 (5): 1060–4.
65. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; 1: CD007893. DOI: 10.1002/14651858
66. Cush JJ, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26 (5): 1176–86.
67. Artz MA, Boots JM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-oflife indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4 (6): 937–45. DOI: 10.1111/j.1600-6143.2004.00427.x
68. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23 (5): 460–8. DOI: 10.1038/ajh.2010.25
69. Wu S, Chen JJ, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9 (2): 117–23. DOI: 10.1016/S1470-2045(08)70003-2
70. Rini BI, Schiller JH, Fruehauf JP et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17 (11): 3841–9. DOI: 10.1158/1078-0432.CCR-10-2806
71. Laragh JH. Renin-Guided Therapy. Clinical Hypertension Review Course Syllabus. Am Soc Hypertens 2005; 353–355.
72. Diaconu C, Nastasa A, Abdul Rehman Z et al. A comparative analysis of the hypertension treatment depending on comorbidities: insights from clinical practice. J Hypertens 2016; 34 (e-Suppl. 1): e320. DOI: 10.1097/01.hjh.0000492280.96930.f6
73. Diaconu C, Istratie B, Nastasa A et al. An age-related comparison between comorbidities and treatment of hypertensive patients. J Hypertens 2016; 34 (e-Suppl. 1): e321. DOI: 10.1097/01.hjh.0000492283.81683.1a.
74. Lowenstein E. Sympathetic nervous system activation and hyperdynamic circulation associated with desflurane: not all isomers are created equal. Anesthesiology 1993; 79 (3): 419–21.
75. Amaranath L, Zanettin GG, Bravo EL et al. Atracurium and pheochromocytoma: a report of three cases. Anesth Analg 1988; 67 (11): 1127–30.
76. Joyce DA, Gubbay SS. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. Br Med J (Clin Res Ed) 1982; 285 (6337): 260–1.
77. Taylor GJ. Cohen Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet Gynecol 1985; 66 (6): 821–2.
78. Bakht FR, Kirshon B, Baker T, Cotton DB. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol 1990; 162 (4): 1065–6.
79. Watson DL, Bhatia RK, Norman GS et al. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol 1989; 74 (4): 573–6.
80. Gorun GS, Dermengiu D, Curca GC et al. Toxicological drivers issues in “legal highs” use. Rom J Leg Med 2010; XVIII (4): 271–9. DOI: 10.4323/rjlm.2010.271
81. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98 (1): 1–14. DOI: 10.1016/j.ijcard.2003.06.039
82. Abhyankar LN, Jones MR, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2012; 120 (4): 494–500. DOI: 10.1289/ehp.1103988
83. Sofer S, Shalev H, Weizman Z et al. Acute pancreatitis in children following envenomation by the yellow scorpion Leiurus quinquestriatus. Toxicon 1991; 29 (1): 125–8.
84. Saadeh AM, Farsakh NA, al-Ali MK. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart 1997; 77 (5) :461–4.
85. World Hypertension League: Nonpharmacological interventions as an adjunct to the pharmacological treatment of hypertension. J Hum Hypertens 1993; 7 (2): 159–64.
86. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125 (1): 14–22. DOI: 10.1016/j.amjmed.2011.05.02
87. Lancu MA, Diaconu C, Dediu G et al. An analysis of hypertensive male patients addresses to a primary practice. J Hypertens 2016; 34 (e-Supplement 2): e323. DOI: 10.1097/01.hjh.0000492291.09500.3a
Авторы
Остроумова Ольга Дмитриевна – д-р мед. наук, проф., проф. каф. факультетской терапии и профболезней ФГБОУ ВО «МГМСУ им. А.И. Евдокимова», зав. лаб. клин. фармакологии и фармакотерапии ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» –
ОСП «Российский геронтологический научно-клинический центр».
E-mail: ostroumova.olga@mail.ru; ORCID: https://orcid.org/0000-0002-0795-8225
Куликова Мария Игоревна – студентка 6-го курса ФГБОУ ВО «МГМСУ им. А.И. Евдокимова». E-mail: mariakulikova123@yandex.ru
Mariia I. Kulikova – Student, A.I. Yevdokimov Moscow State University of Medicine and Dentistry. E-mail: mariakulikova123@yandex.ru
ОСП «Российский геронтологический научно-клинический центр».
E-mail: ostroumova.olga@mail.ru; ORCID: https://orcid.org/0000-0002-0795-8225
Куликова Мария Игоревна – студентка 6-го курса ФГБОУ ВО «МГМСУ им. А.И. Евдокимова». E-mail: mariakulikova123@yandex.ru
________________________________________________
Mariia I. Kulikova – Student, A.I. Yevdokimov Moscow State University of Medicine and Dentistry. E-mail: mariakulikova123@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.